High Incidence of ErbB3, ErbB4, and MET Expression in Ovarian Cancer

被引：42

作者：

Davies, Suzy ^{[1
]}

Holmes, Anna ^{[2
]}

Lomo, Lesley ^{[2
]}

Steinkamp, Mara P. ^{[2
]}

Kang, Huining ^{[3
]}

Muller, Carolyn Y. ^{[1
]}

Wilson, Bridget S. ^{[2
,4
]}

机构：

[1] Univ New Mexico, Hlth Sci Ctr, Dept Obstet & Gynecol, Albuquerque, NM 87131 USA

[2] Univ New Mexico, Hlth Sci Ctr, Dept Pathol, Albuquerque, NM 87131 USA

[3] Univ New Mexico, Hlth Sci Ctr, Dept Internal Med, Albuquerque, NM 87131 USA

[4] Univ New Mexico, Hlth Sci Ctr, Ctr Canc, Albuquerque, NM 87131 USA

来源：

INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY | 2014年 / 33卷 / 04期

关键词：

ErbB; MET; Ovarian cancer; Tissue array; PHASE-II TRIAL; TYROSINE KINASE INHIBITOR; HEPATOCYTE GROWTH-FACTOR; EPITHELIAL OVARIAN; HER-2/NEU EXPRESSION; MESSENGER-RNA; BEVACIZUMAB; PERITONEAL; AMPLIFICATION; FAMILY;

D O I：

10.1097/PGP.0000000000000081

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Ovarian cancer is the leading cause of death from gynecologic cancers in the United States. Failure may be due to variable expression and/or complex interactions of growth factor receptors in individual tumors. As ErbB3-MET cooperativity is implicated in solid tumor resistance to EGFR/ErbB2 inhibitors, we evaluated expression of MET and all 4 ErbB family members in ovarian cancers. Tissue arrays were prepared from archival formalin-fixed paraffin-embedded tumor samples, including 202 ovarian carcinomas (Stage I-IV) and controls. Of 202 patient samples, only 25% were positive for EGFR and 35% for ErbB2 expression. ErbB3, ErbB4, and MET showed marked expression in 76%, 98%, and 96% of cases. Consistent with high incidence, there was no significant correlation for expression of ErbB3, ErbB4, or MET with outcome. On the basis of their high expression in the majority of cases, inhibitors targeting ErbB3, ErbB4, and/or MET may be broadly applicable as therapeutic agents in this disease.

引用

页码：402 / 410

页数：9

共 48 条

[1] HER3 mRNA as a predictive biomarker in anticancer therapy [J].

Amler, Lukas C. .

EXPERT OPINION ON BIOLOGICAL THERAPY, 2010, 10 (09) :1343-1355

[2] Targeted Therapies in Epithelial Ovarian Cancer [J].

Barrena Medel, Nicanor I. ;

Wright, Jason D. ;

Herzog, Thomas J. .

JOURNAL OF ONCOLOGY, 2010, 2010

[3] Integrated genomic analyses of ovarian carcinoma [J].

Bell, D. ;

Berchuck, A. ;

Birrer, M. ;

Chien, J. ;

Cramer, D. W. ;

Dao, F. ;

Dhir, R. ;

DiSaia, P. ;

Gabra, H. ;

Glenn, P. ;

Godwin, A. K. ;

Gross, J. ;

Hartmann, L. ;

Huang, M. ;

Huntsman, D. G. ;

Iacocca, M. ;

Imielinski, M. ;

Kalloger, S. ;

Karlan, B. Y. ;

Levine, D. A. ;

Mills, G. B. ;

Morrison, C. ;

Mutch, D. ;

Olvera, N. ;

Orsulic, S. ;

Park, K. ;

Petrelli, N. ;

Rabeno, B. ;

Rader, J. S. ;

Sikic, B. I. ;

Smith-McCune, K. ;

Sood, A. K. ;

Bowtell, D. ;

Penny, R. ;

Testa, J. R. ;

Chang, K. ;

Dinh, H. H. ;

Drummond, J. A. ;

Fowler, G. ;

Gunaratne, P. ;

Hawes, A. C. ;

Kovar, C. L. ;

Lewis, L. R. ;

Morgan, M. B. ;

Newsham, I. F. ;

Santibanez, J. ;

Reid, J. G. ;

Trevino, L. R. ;

Wu, Y. -Q. ;

Wang, M. .

NATURE, 2011, 474 (7353) :609-615

[4] Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic oncology group study [J].

Burger, Robert A. ;

Sill, Michael W. ;

Monk, Bradley J. ;

Greer, Benjamin E. ;

Sorosky, Joel I. .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (33) :5165-5171

[5] Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer [J].

Burger, Robert A. ;

Brady, Mark F. ;

Bookman, Michael A. ;

Fleming, Gini F. ;

Monk, Bradley J. ;

Huang, Helen ;

Mannel, Robert S. ;

Homesley, Howard D. ;

Fowler, Jeffrey ;

Greer, Benjamin E. ;

Boente, Matthew ;

Birrer, Michael J. ;

Liang, Sharon X. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (26) :2473-2483

[6] HER3 Comes of Age: New Insights into Its Functions and Role in Signaling, Tumor Biology, and Cancer Therapy [J].

Campbell, Marcia R. ;

Amin, Dhara ;

Moasser, Mark M. .

CLINICAL CANCER RESEARCH, 2010, 16 (05) :1373-1383

[7] Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer [J].

Campos, S ;

Hamid, C ;

Seiden, MV ;

Oza, A ;

Plante, M ;

Potkul, RK ;

Lenehan, PF ;

Kaldjian, EP ;

Varterasian, ML ;

Jordan, C ;

Charbonneau, C ;

Hirte, H .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (24) :5597-5604

[8] Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer [J].

Cannistra, Stephen A. ;

Matulonis, Ursula A. ;

Penson, Richard T. ;

Hambleton, Julie ;

Dupont, Jakob ;

Mackey, Howard ;

Douglas, Jeffrey ;

Burger, Robert A. ;

Armstrong, Deborah ;

Wenham, Robert ;

McGuire, William .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (33) :5180-5186

[9] Drug development of MET inhibitors: targeting oncogene addiction and expedience [J].

Comoglio, Paolo M. ;

Giordano, Silvia ;

Trusolino, Livio .

NATURE REVIEWS DRUG DISCOVERY, 2008, 7 (06) :504-516

[10] Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer [J].

Eder, Joseph Paul ;

Woude, George F. Vande ;

Boerner, Scott A. ;

LoRusso, Patricia M. .

CLINICAL CANCER RESEARCH, 2009, 15 (07) :2207-2214

← 1 2 3 4 5 →